Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential TherapyHidekatsu Kuroda, Yasuhiro Takikawa, Go Igarashi et al.|Liver Cancer|2022Cited by 45
Environmental factors, medical and family history, and comorbidities associated with primary biliary cholangitis in Japan: a multicenter case–control studyKosuke Matsumoto, Atsushi Tanaka, Satoko Ohfuji et al.|Journal of Gastroenterology|2021Cited by 34
Activated cholangiocytes release macrophage-polarizing extracellular vesicles bearing the DAMP S100A11Tomohiro Katsumi, Gregory J. Gores|American Journal of Physiology-Cell Physiology|2019Cited by 30
Influence of skeletal muscle volume loss during lenvatinib treatment on prognosis in unresectable hepatocellular carcinoma: a multicenter study in Tohoku, JapanMasashi Fujita, Hiromasa Ohira, Kazumichi Abe et al.|Scientific Reports|2022Cited by 17